No Correlation between the Molecular Subtype of COL1A1–PDGFB Fusion Gene and the Clinico-Histopathological Features of Dermatofibrosarcoma Protuberans
Damien Giacchero(Université Paris-Est Créteil), Florence Pédeutour(Centre National de la Recherche Scientifique), Dominique Ranchère‐Vince(Centre Léon Bérard), Philippe Saïag(Université de Versailles Saint-Quentin-en-Yvelines), Paulo Nuin(Queen's University), Philippe Terrier(Institut Gustave Roussy), É. Estève(Centre hospitalier universitaire d'Orléans), J.‐P. Lacour(Centre Hospitalier Universitaire de Nice), Georges Maire(Centre National de la Recherche Scientifique), B. Guillot(Université de Montpellier), F. Berthier, Sylvie Fraïtag(Délégation Paris 5), Jean Michel Coindre(Institut Bergonié), P. Celérier(Centre Hospitalier de La Rochelle), A. Carlotti(Délégation Paris 5), Nathalie Ebran(Centre National de la Recherche Scientifique)
Cited by 34
Related Papers
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
|New England Journal of Medicine|2016|2.1k
Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial
|The Lancet Oncology|2017|780
Inefficacy of Immediate Node Dissection in Stage 1 Melanoma of the Limbs
|New England Journal of Medicine|1977|667
Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2)*
|British Journal of Dermatology|2020|590
Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline – Update 2016
|European Journal of Cancer|2016|579